How well does vaccination work in residents of long-term care homes

McMaster researchers aim to find out
18-Mar-2021 10:55 AM EDT, by McMaster University

Newswise — MONTREAL, MARCH 18, 2021 – Long-term care homes have been at the epicentre of the COVID-19 pandemic in Canada, with 70 percent of COVID-19 deaths having occurred in long-term care or nursing homes. 

The Government of Canada, through its COVID-19 Immunity Task Force (CITF), is supporting a study led by McMaster University researchers aimed at understanding how well vaccination works in residents of long-term care homes and which factors may be directly linked to outbreaks. Approximately $5 million is being provided for this study, one of the largest single studies focusing on long-term care homes in Canada. 

The study, which is in partnership with Schlegel Villages, St. Joseph’s Health System, and Health Sciences North Research Institute, will involve more than 2,000 residents, staff, and visitors of long-term care homes in Ontario over the course of a year. 

“We aim to determine how well vaccination works in residents of long-term care homes and discover whether a resident’s previous exposure to the virus or immune system response can protect them or make them vulnerable to further infection,” says Andrew Costa, PhD, co-principal investigator of the study, and Associate Professor of health research methods, evidence, and impact at McMaster. 

The team will also determine what factors within long-term care homes may be directly associated with outbreaks, and whether those homes with previous infections are likely to have future outbreaks. 

“We’ll be mapping this information with other available data to better understand the spread of the virus and immunity response across the province,” adds Dr. Costa. 

Co-principal investigator Dawn Bowdish, PhD, an immunologist and professor of medicine at McMaster, adds that outbreaks can still be expected, despite widespread vaccinations. 

“Although most residents are dangerously susceptible to COVID-19, some are resilient. Learning about how the immune system helps some residents teaches us how to make better vaccines and protect residents from future outbreaks,” she says. 

The research team is working with scientific partners at the Ontario Ministry of Health, Public Health Ontario, Schlegel-UW Research Institute for Aging (RIA), University of Toronto, the Health Sciences North Research Institute, St. Mary’s General Hospital and the University of Waterloo. PointClickCare Technologies and the Lung Health Foundation are supporting this research.

“Our research will influence health policy quickly because we are collaborating directly with provincial policymakers and COVID-19 decision-makers,” Dr. Bowdish explains. 

“Our team members and residents are proud to be part of this cutting edge and important study,” says James Schlegel, President and CEO of Schlegel Villages. “The results of this study will contribute greatly to a more robust understanding of COVID-19 in long-term care homes and will help us keep residents safe and healthy. We are honoured to work with the McMaster team and other partners to conduct this ground-breaking research.”

“This study presents an important opportunity for our member organizations to continue to learn more about COVID-19, its transmission in long-term care homes and what effect vaccination is having on virus transmission,” says David Wormald, President of St. Joseph's Health Centre Guelph and St. Joseph's Lifecare Centre Brantford, and Vice-President of elder care for St. Joseph's Health System. “We have come a long way in our understanding of COVID-19 in the last year and the continued learnings will help in our fight against COVID-19 at St. Joseph’s Health System and beyond.”

“COVID-19 has taken an enormous toll on the elderly and studies like this one are needed so we can better protect them going forward,” says Allison McGeer, MD, CITF Leadership Group member. “We encourage teams to work with those who can use the findings and implement them quickly, such as government, public health authorities, and key long-term care facility operators. This study is doing that.”

“Sadly, seniors have been disproportionately impacted by the COVID-19 pandemic,” says Dr. Theresa Tam, Canada’s Chief Public Health Officer. “This research collaboration will enhance our understanding of vaccine-induced immunity in seniors living in long-term care homes in order to better protect these residents in future”. 

The project is part of Canada’s Global Nexus for Pandemics and Biological Threats, an international network based at McMaster, with scientists, clinicians, engineers, social scientists and other experts working collaboratively to prevent future pandemics and mitigate global health threats.

 

About the COVID-19 Immunity Task Force In late April 2020, the Government of Canada established the COVID-19 Immunity Task Force with a two-year mandate. The Task Force is overseen by a Leadership Group of volunteers that includes leading Canadian scientists and experts from universities and healthcare homes across Canada who are focused on understanding the nature of immunity arising from the novel coronavirus that causes COVID-19. To that end, the CITF is supporting numerous studies to determine the extent of SARS-CoV-2 infection in Canada (in the general population as well as in specific communities and priority populations), understand the nature of immunity following infection, develop improved antibody testing methods, and help monitor the effectiveness and safety of vaccines as they are rolled out across Canada. The Task Force and its Secretariat accordingly work closely with a range of partners, including governments, public health agencies, institutions, health organizations, research teams, other task forces, and engages communities and stakeholders. Most recently, the Task Force has been asked to support vaccine surveillance, effectiveness and safety as part of its overall objective to generate data and ideas that inform interventions aimed at slowing—and ultimately stopping—the spread of SARS-CoV-2 in Canada. For more information visit: www.covid19immunitytaskforce.ca

 

 

EDITORS:

 

Photos and B-roll:

https://shared-assets.adobe.com/link/8ce24736-9779-407c-6c1b-fa86ffee4f25

 

Video:

https://vimeo.com/524364338

 

 

 

 

 

 




Filters close

Showing results

110 of 5474
Newswise: Among COVID-19 survivors, an increased risk of death, serious illness
Released: 22-Apr-2021 11:55 AM EDT
Among COVID-19 survivors, an increased risk of death, serious illness
Washington University in St. Louis

A new study from Washington University School of Medicine in St. Louis shows that even mild cases of COVID-19 increase the risk of death in the six months following diagnosis and that this risk increases with disease severity. The comprehensive study also catalogues the wide-ranging and long-term health problems often triggered by the infection, even among those not hospitalized.

Released: 22-Apr-2021 11:25 AM EDT
Artificial intelligence model predicts which key of the immune system opens the locks of coronavirus
University of Helsinki

The human immune defense is based on the ability of white blood cells to accurately identify disease-causing pathogens and to initiate a defense reaction against them

Newswise: Faster Air Exchange in Buildings Not Always Beneficial for Coronavirus Levels
AUDIO
Released: 22-Apr-2021 8:00 AM EDT
Faster Air Exchange in Buildings Not Always Beneficial for Coronavirus Levels
Pacific Northwest National Laboratory

Vigorous and rapid air exchanges might not always be a good thing when it comes to levels of coronavirus particles in a multiroom building, according to a new modeling study. Particle levels can spike in downstream rooms shortly after rapid ventilation.

Released: 21-Apr-2021 5:20 PM EDT
Research Results: Double Masking During the COVID-19 Pandemic
Environmental Protection Agency - Center for Environmental Solutions and Emergency Response (CESER)

EPA, along with their co-authors at UNC, recently published an article titled “Fitted Filtration Efficiency of Double Masking During the COVID-19 Pandemic.”

Released: 21-Apr-2021 3:55 PM EDT
ACTG Adds First Polyclonal Antibody to ACTIV-2 Outpatient Treatment Study for COVID-19
University of California, Los Angeles (UCLA), Health Sciences

The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, has added SAB-185, a polyclonal antibody therapy, to the COVID-19 outpatient treatment study.

access_time Embargo lifts in 2 days
Embargo will expire: 27-Apr-2021 11:00 AM EDT Released to reporters: 21-Apr-2021 3:45 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 27-Apr-2021 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 21-Apr-2021 2:10 PM EDT
New insights on inflammation in COVID-19
Wiley

Severe cases of COVID-19 can involve extensive inflammation in the body, and clinicians have wondered if this state is similar to what are called cytokine storm syndromes, in which the immune system produces too many inflammatory signals that can sometimes lead to organ failure and death.

Newswise: TTUHSC Medical Students Educate about COVID-19 Vaccination Misconceptions with Outreach to Hispanic Communities
Released: 21-Apr-2021 2:00 PM EDT
TTUHSC Medical Students Educate about COVID-19 Vaccination Misconceptions with Outreach to Hispanic Communities
Texas Tech University Health Sciences Center

Student members of the Texas Tech University Health Sciences Center (TTUHSC) Latino Medical Student Association (LMSA) answered questions and myths about the COVID-19 vaccine for the Hispanic community.

Newswise: Story Tips from Johns Hopkins Experts on COVID-19
Released: 21-Apr-2021 11:00 AM EDT
Story Tips from Johns Hopkins Experts on COVID-19
Johns Hopkins Medicine

NEWS STORIES IN THIS ISSUE: PREGNANT AFTER THE FIRST DOSE OF COVID-19 VACCINE — NOW WHAT? STUDY SHOWS VACCINES MAY PROTECT AGAINST NEW COVID-19 STRAINS … AND MAYBE THE COMMON COLD EXPANDED DASHBOARD TOOL RANKS ACCESSIBILITY OF STATE VACCINE WEBSITES


Showing results

110 of 5474

close
1.46147